Moleculin Biotech Reports Q3 2026 Financial Results

What Happened
On August 14, 2026, Moleculin Biotech, Inc. (MBRX) issued a press release announcing its financial results for the quarter ended June 30, 2026 and recent operational highlights. The press release was attached to the Form 8‑K and is incorporated by reference.

Key Details

• Filing date: August 14, 2026 (Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: Quarter ended June 30, 2026.
• Exhibit: Press release dated August 14, 2026 filed as Exhibit 99.1 and incorporated by reference.
• The filing also includes standard interactive data (Inline XBRL) as noted under Item 9.01.

Why It Matters
This 8‑K notifies investors that Moleculin has released its quarterly earnings and operational update — information that may include revenue, expenses, cash position and program milestones. Investors should review the attached press release (Exhibit 99.1) and any related SEC filings for the specific financial figures and clinical or operational developments to assess the company’s near‑term outlook and investment implications.